SCHEDULE: Saturn V Capital Management Discloses 5.2% Stake in Monopar Therapeutics

Saturn V Capital Management LP and Xiaoying Tian have reported beneficial ownership of 345,626 shares, representing 5.2% of Monopar Therapeutics Inc.'s common stock.

Summary

• Saturn V Capital Management LP, acting as the investment manager for various pooled investment vehicles and managed accounts (Clients), along with Xiaoying Tian, has filed a Schedule 13G.
• They collectively beneficially own 345,626 shares of Monopar Therapeutics Inc. common stock.
• This ownership stake represents 5.2% of the total outstanding shares.
• The filing indicates that Saturn V Capital Management LP has shared voting power and shared dispositive power over these shares.
• Xiaoying Tian, as the Managing Member of SVCM GP LLC (the general partner of Saturn V Capital Management LP), also has shared voting and dispositive power.
• Both Saturn V Capital Management LP and Xiaoying Tian disclaim beneficial ownership of the shares held by the Clients, as no single client holds 5% or more of the outstanding shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It provides transparency on ownership but lacks operational or financial performance data, making it difficult to assess the company's current health or future prospects based solely on this document.

Positives

• Disclosure of a significant ownership stake (5.2%) by an investment manager can indicate confidence in the company's prospects.
• The filing is made in accordance with regulatory requirements, ensuring transparency for investors.

Negatives

• The filing does not contain any financial performance data or operational updates, limiting the assessment of the company's health.
• The disclaimed beneficial ownership by Saturn V Capital Management LP and Xiaoying Tian suggests their control is indirect and spread across multiple clients.

Risks

• Potential for future changes in ownership or investment strategy by Saturn V Capital Management LP could impact Monopar Therapeutics' stock.
• As a Schedule 13G filing, it indicates passive investment, but a shift to an activist stance, though not implied, is always a potential risk for any significant shareholder.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Monopar Therapeutics Inc.

Management Comments

• Saturn V Capital Management LP acts as the investment manager of certain pooled investment vehicles and managed accounts (collectively the "Clients") in which such shares referred to above are held. As a result, Saturn V Capital Management LP possesses the power to vote and dispose or direct the disposition of all the shares beneficially owned by the Clients.
• No Client holds or beneficially owns five percent or more of the outstanding shares of the Issuer. Saturn V Capital Management LP disclaims beneficial ownership of any of the shares held by the Clients.
• Ms. Tian is the Managing Member of SVCM GP LLC, the general partner of Saturn V Capital Management LP, the Investment Manager of the Clients. As a result, Ms. Tian possesses the power to vote and dispose or direct the disposition of all the shares beneficially owned by the Clients. Ms. Tian disclaims beneficial ownership of any of the shares held by the Clients.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment managers accumulating stakes in publicly traded companies. The 5.2% threshold often signifies a significant passive investment, potentially positioning Saturn V Capital Management LP as a notable shareholder in the biotechnology sector where Monopar Therapeutics operates.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant passive investor may influence market perception and trading activity.
• Management: Awareness of a substantial shareholder may influence strategic decisions and communication efforts.
• Creditors: No direct impact as the filing does not concern debt or financial distress.

Next Steps

• Monitor future filings from Saturn V Capital Management LP and Xiaoying Tian for any changes in ownership or investment strategy.
• Observe Monopar Therapeutics Inc.'s future performance and disclosures for insights into the company's operational and financial health.

Key Dates

Keywords

Monopar Therapeutics, Schedule 13G, Saturn V Capital Management LP, Xiaoying Tian, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Passive Investment